HK1139868A1 - Improved medicinal compositions comprising buprenorphine and nalmefene - Google Patents

Improved medicinal compositions comprising buprenorphine and nalmefene

Info

Publication number
HK1139868A1
HK1139868A1 HK10106539.3A HK10106539A HK1139868A1 HK 1139868 A1 HK1139868 A1 HK 1139868A1 HK 10106539 A HK10106539 A HK 10106539A HK 1139868 A1 HK1139868 A1 HK 1139868A1
Authority
HK
Hong Kong
Prior art keywords
nalmefene
buprenorphine
medicinal compositions
improved medicinal
improved
Prior art date
Application number
HK10106539.3A
Other languages
English (en)
Inventor
Christopher Bourne Chapleo
Neil Hyde
Original Assignee
Rb Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rb Pharmaceuticals Ltd filed Critical Rb Pharmaceuticals Ltd
Publication of HK1139868A1 publication Critical patent/HK1139868A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK10106539.3A 2007-03-01 2010-07-06 Improved medicinal compositions comprising buprenorphine and nalmefene HK1139868A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0703933A GB2447013A (en) 2007-03-01 2007-03-01 Analgesic composition containing buprenorphone and nalmefene
PCT/GB2008/000522 WO2008104736A1 (en) 2007-03-01 2008-02-15 Improved medicinal compositions comprising buprenorphine and nalmefene

Publications (1)

Publication Number Publication Date
HK1139868A1 true HK1139868A1 (en) 2010-09-30

Family

ID=37965707

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10106539.3A HK1139868A1 (en) 2007-03-01 2010-07-06 Improved medicinal compositions comprising buprenorphine and nalmefene

Country Status (22)

Country Link
US (1) US8497280B2 (xx)
EP (1) EP2114452B1 (xx)
JP (1) JP5577102B2 (xx)
KR (1) KR101437461B1 (xx)
CN (1) CN101622012B (xx)
AR (1) AR065582A1 (xx)
AU (1) AU2008220572B2 (xx)
BR (1) BRPI0807903A2 (xx)
CA (1) CA2678568C (xx)
CL (1) CL2008000607A1 (xx)
DK (1) DK2114452T3 (xx)
ES (1) ES2476865T3 (xx)
GB (1) GB2447013A (xx)
HK (1) HK1139868A1 (xx)
HR (1) HRP20140591T1 (xx)
MX (1) MX2009009134A (xx)
PE (2) PE20090625A1 (xx)
PL (1) PL2114452T3 (xx)
PT (1) PT2114452E (xx)
TW (1) TWI468163B (xx)
WO (1) WO2008104736A1 (xx)
ZA (1) ZA200905692B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102128C2 (xx) * 2008-12-05 2013-06-10 Х. Луннбек А/С Налмефену гідрохлориду дигідрат$налмефена гидрохлорида дигидрат
MX2011012502A (es) * 2009-05-25 2011-12-12 Lundbeck & Co As H Metodo para la preparacion de hidrocloruro de nalmefeno.
SG11201406025UA (en) 2012-04-17 2014-11-27 Purdue Pharma Lp Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN103637983B (zh) * 2013-12-16 2017-08-04 科贝源(北京)生物医药科技有限公司 一种含有盐酸纳美芬的药物组合物及其制备方法
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN104922061B (zh) * 2015-05-26 2017-09-22 成都天台山制药有限公司 盐酸纳美芬注射液药物组合物和制法
EP3755310A4 (en) * 2018-02-22 2021-05-19 Avior, Inc. TRANSMUCOSAL FILM COMPOSITION AND METHOD OF MANUFACTURING AND USING THEREOF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
WO2007145704A2 (en) * 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US20110015168A1 (en) * 2007-01-19 2011-01-20 Mitchell Keegan Methods for increasing levels of human fetal hemoglobin

Also Published As

Publication number Publication date
ES2476865T3 (es) 2014-07-15
KR20090115862A (ko) 2009-11-09
BRPI0807903A2 (pt) 2014-06-17
JP2010520184A (ja) 2010-06-10
AU2008220572B2 (en) 2014-03-27
HRP20140591T1 (hr) 2014-09-12
AR065582A1 (es) 2009-06-17
WO2008104736A1 (en) 2008-09-04
TW200900067A (en) 2009-01-01
PE20090625A1 (es) 2009-06-04
US20100152222A1 (en) 2010-06-17
PT2114452E (pt) 2014-07-15
TWI468163B (zh) 2015-01-11
PL2114452T3 (pl) 2014-09-30
CN101622012B (zh) 2012-05-30
US8497280B2 (en) 2013-07-30
CL2008000607A1 (es) 2008-10-03
KR101437461B1 (ko) 2014-09-05
JP5577102B2 (ja) 2014-08-20
CN101622012A (zh) 2010-01-06
MX2009009134A (es) 2009-09-03
EP2114452B1 (en) 2014-04-09
AU2008220572A1 (en) 2008-09-04
PE20120956A1 (es) 2012-08-01
CA2678568A1 (en) 2008-09-04
DK2114452T3 (da) 2014-06-30
GB2447013A (en) 2008-09-03
ZA200905692B (en) 2010-10-27
GB0703933D0 (en) 2007-04-11
CA2678568C (en) 2015-06-16
EP2114452A1 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
HRP20182124T1 (hr) Farmaceutski sastavi s trenutnim oslobađanjem koji sadrže oksikodon i nalokson
ZA200905689B (en) Improved medicinal compositions comprising buprenorphine and naltrexone
ZA200905691B (en) Improved medicinal compositions comprising buprenorphine and naloxone
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
ZA201203709B (en) Immunogenic compositions and methods
ZA201001300B (en) Antigen-asjuvant compositions and methods
ZA200804305B (en) Pharmaceutical compositions comprising buprenorphine
EP2086318A4 (en) NEUROPROTEKTIVE COMPOSITIONS AND METHOD
ZA201008887B (en) Oral compositions and uses thereof
ZA201007920B (en) Oral compositions and uses thereof
ZA200807614B (en) Buprenorphine derivatives and uses thereof
GB0721291D0 (en) Methods and compositions
HK1139868A1 (en) Improved medicinal compositions comprising buprenorphine and nalmefene
HK1139153A1 (en) Quinolone compound and pharmaceutical composition
GB0719526D0 (en) Compositions and methods
GB0715428D0 (en) Compositions and uses thereof
GB0701170D0 (en) Compositions and uses thereof
GB0701171D0 (en) Compositions and uses thereof
GB0725264D0 (en) Compositions and uses thereof
GB0906046D0 (en) Nalmefene compositions and their therapeutic use
GB0906042D0 (en) Nalmefene compositions and their therapeutic use
GB0906045D0 (en) Nalmefene compositions and their therapeutic use
GB0906043D0 (en) Nalmefene compositions and their therapeutic use
GB0906044D0 (en) Nalmefene compositions and their therapeutic use
GB0724549D0 (en) Compositions and methods

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170215